Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Kerry L. Reynolds"'
Autor:
Benjamin C. Park, Sathya Narayanan, Alexander Gavralidis, Fei Ye, Run Fan, Ryan J. Sullivan, Genevieve Boland, Kerry L Reynolds, Justin M. Balko, Matteo S. Carlino, Georgina V. Long, Leyre Zubiri, Alexander M. Menzies, Douglas B. Johnson
Publikováno v:
OncoImmunology. 12
Autor:
Shruti, Gupta, Clara, Garcia-Carro, Jason M, Prosek, Ilya, Glezerman, Sandra M, Herrmann, Pablo, Garcia, Ala, Abudayyeh, Nuttha, Lumlertgul, A Bilal, Malik, Sebastian, Loew, Pazit, Beckerman, Amanda D, Renaghan, Christopher A, Carlos, Arash, Rashidi, Zain, Mithani, Priya, Deshpande, Sunil, Rangarajan, Chintan V, Shah, Sophie De, Seigneux, Luca, Campedel, Abhijat, Kitchlu, Daniel Sanghoon, Shin, Gaia, Coppock, David I, Ortiz-Melo, Ben, Sprangers, Vikram, Aggarwal, Karolina, Benesova, Rimda, Wanchoo, Naoka, Murakami, Frank B, Cortazar, Kerry L, Reynolds, Meghan E, Sise, Maria Jose, Soler, David E, Leaf, Maria Josep, Carreras
Publikováno v:
Scientia
BackgroundCorticosteroids are the mainstay of treatment for immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI), but the optimal duration of therapy has not been established. Prolonged use of corticosteroids can cause numerous adver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97a57dfebd831dff1bf7e025afc0c37f
https://lirias.kuleuven.be/handle/20.500.12942/703389
https://lirias.kuleuven.be/handle/20.500.12942/703389
Autor:
Bruce C Tiu, Leyre Zubiri, James Iheke, Vartan Pahalyants, Nicholas Theodosakis, Pearl Ugwu-Dike, Jayhyun Seo, Kimberly Tang, Meghan E Sise, Ryan Sullivan, Jarushka Naidoo, Meghan J Mooradian, Yevgeniy R Semenov, Kerry L Reynolds
Publikováno v:
Journal for immunotherapy of cancer. 10(6)
BackgroundImmune checkpoint inhibitors (ICIs) have improved survival and are increasingly used for non-small cell lung cancer. However, use may be limited by immune-related adverse events such as checkpoint-inhibitor pneumonitis (CIP). Literature est
Autor:
Ayo S. Falade, Kerry L. Reynolds, Leyre Zubiri, Vikram Deshpande, Florian J. Fintelmann, Michael Dougan, Meghan J. Mooradian
Publikováno v:
Frontiers in Immunology. 13
Since the first approval of immune checkpoint inhibitors (ICIs) in 2011, these agents have rapidly become an integral treatment option across tumor types. However, with the increased adoption of ICIs, the incidence of immune-related adverse events (i
Autor:
Meghan E Sise, Qiyu Wang, Harish Seethapathy, Daiana Moreno, Destiny Harden, R Neal Smith, Ivy A Rosales, Robert B Colvin, Sarah Chute, Lynn D Cornell, Sandra M Herrmann, Riley Fadden, Ryan J Sullivan, Nancy J Yang, Sara Barmettler, Sophia Wells, Shruti Gupta, Alexandra-Chloe Villani, Kerry L Reynolds, Jocelyn Farmer
Publikováno v:
Journal for ImmunoTherapy of Cancer. 11:e006222
BackgroundNon-invasive biomarkers of immune checkpoint inhibitor-associated acute tubulointerstitial nephritis (ICI-nephritis) are urgently needed. Because ICIs block immune checkpoint pathways that include cytotoxic T lymphocyte antigen 4 (CTLA4), w
Autor:
Leyre Zubiri, Vartan Pahalyants, Jayhyun Seo, Bruce Tiu, Nicholas Theodosakis, Kerry L. Reynolds, Ryan J. Sullivan, Kimberly Tang, P. Ugwu-Dike, Meghan J. Mooradian, Yevgeniy R. Semenov, James Iheke
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundImmune checkpoint inhibitors (ICI) generate T-cell mediated anti-tumor responses that are effective across numerous malignancies, but their use is frequently complicated by immune-related adverse events (irAEs). irAEs may lead to treatment
Autor:
Enriqueta Felip, Sophie Papa, Shuchi Anand, Karolina Benesova, Ala Abudayyeh, Omar Mamlouk, Umut Selamet, Grace Cherry, Sunandana Chandra, Sandra M Herrmann, Maria Jose Soler, Abhijat Kitchlu, Jamie S Lin, Kerry L Reynolds, Osama E Rahma, Elizabeth M Gaughan, Eva Muñoz-Couselo, Jamie S Hirsch, Pablo Garcia, Meghan D Lee, Harish Seethapathy, Ian A Strohbehn, Meghan E Sise, Wei-Ting Chang, Els Wauters, Lucy Flanders, Deborah Schrag, Thibaud Koessler, Mark Eijgelsheim, Shruti Gupta, Frank B Cortazar, Samuel A P Short, Jason M Prosek, Sethu M Madhavan, Ilya Glezerman, Shveta S Motwani, Naoka Murakami, Rimda Wanchoo, David I Ortiz-Melo, Arash Rashidi, Ben Sprangers, Vikram Aggarwal, A Bilal Malik, Sebastian Loew, Christopher A Carlos, Pazit Beckerman, Zain Mithani, Chintan V Shah, Amanda D Renaghan, Sophie De Seigneux, Luca Campedel, Daniel Sanghoon Shin, Sunil Rangarajan, Priya Deshpande, Gaia Coppock, Dwight H. Owen, Marium Husain, Clara Garcia-Carro, Sheila Bermejo, Nuttha Lumlertgul, Nina Seylanova, Busra Isik, Aydin Kaghazchi, Yuriy Khanin, Sheru K Kansal, Kai M Schmidt-Ott, Raymond K Hsu, Maria C Tio, Suraj Sarvode Mothi, Harkarandeep Singh, Kenar D Jhaveri, David E Leaf, Corinne Isnard Bagnis, Suraj S Mothi, Weiting Chang, Vipulbhai Sakhiya, Daniel Stalbow, Sylvia Wu, Armando Cennamo, Anne Rigg, Nisha Shaunak, Zoe A Kibbelaar, Harish S Seethapathy, Meghan Lee, Ian A Strohbhen, Ilya G Glezerman, Dwight H Owen, Sharon Mini, Andrey Kisel, Nicole Albert, Katherine Carter, Vicki Donley, Tricia Young, Heather Cigoi, Els Wauters Ben Sprangers, Javier A Pagan, Jonathan J Hogan, Valda Page, Samuel AP Short, Maria Josep Carreras
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Scientia
Journal for immunotherapy of cancer, 9(10):e003467. BMC
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Scientia
Journal for immunotherapy of cancer, 9(10):e003467. BMC
BackgroundImmune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) has emerged as an important toxicity among patients with cancer.MethodsWe collected data on 429 patients with ICPi-AKI and 429 control patients who received ICPis contemp
Autor:
Kerry L. Reynolds, Elad Sharon, Meghan E. Sise, Douglas B. Johnson, Laura A. Petrillo, William C Louv, Mace L. Rothenberg, Michael Dougan, Sean Khozin, Aakanksha Khandelwal, Teilo H Schaller, Amanda C. Guidon, Shaily Arora, Ravikumar Komandur Elayavilli, Osama E. Rahma, Alexandra-Chloé Villani, Leyre Zubiri
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, improving outcomes in patients with advanced malignancies. The use of ICIs in clinical practice, and the number of ICI clinical trials, are rapidly increasing. The use o
Autor:
Amanda C. Guidon, Vern C. Juel, William C Louv, Justine V. Cohen, Jenny J. Linnoila, David A. Reardon, Leyre Zubiri, Christopher T. Doughty, Priscilla K. Brastianos, Jeffrey T. Guptill, Jeffrey M. Gelfand, Douglas B. Johnson, Nicole R. LeBoeuf, Divyanshu Dubey, Jorg Dietrich, Andrew L. Mammen, Jarushka Naidoo, Tomas G. Neilan, Anthony A. Amato, Bart K Chwalisz, Robert Kadish, Ryan J. Sullivan, Noah Kolb, Allison Betof Warner, Karin Woodman, Michael Dougan, Nancy Wang, Meghan J. Mooradian, Bianca Santomasso, Teilo H Schaller, Maria Martinez-Lage, Krista M. Rubin, Tracey A. Cho, James M. Hillis, Leeann B Burton, Kerry L. Reynolds, Stacey L. Clardy
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Expanding the US Food and Drug Administration–approved indications for immune checkpoint inhibitors in patients with cancer has resulted in therapeutic success and immune-related adverse events (irAEs). Neurologic irAEs (irAE-Ns) have an incidence
Autor:
Vineet K. Raghu, Leyre Zubiri, Jingyi Gong, Daniel A. Zlotoff, Anju Nohria, Zsofia D. Drobni, Carlos Gongora, Hannah K Gilman, Thiago Quinaglia, Raza M. Alvi, Sarah Hartmann, Ryan J. Sullivan, Amna Zafar, Meghan E. Sise, Kerry L. Reynolds, Tomas G. Neilan
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
BackgroundThere are limited data on the occurrence, associations and outcomes of pericardial effusions and pericarditis on or after treatment with immune checkpoint inhibitors (ICIs).MethodsThis was a retrospective study at a single academic center t